ROCK and Rho: Promising therapeutic targets to ameliorate pulmonary fibrosis

David W H Riches; Donald S Backos; Elizabeth F Redente

doi:10.1016/j.ajpath.2015.01.005

ROCK and Rho: Promising therapeutic targets to ameliorate pulmonary fibrosis

Am J Pathol. 2015 Apr;185(4):909-12. doi: 10.1016/j.ajpath.2015.01.005. Epub 2015 Feb 14.

Authors

David W H Riches¹, Donald S Backos², Elizabeth F Redente³

Affiliations

¹ Program in Cell Biology, Department of Pediatrics, National Jewish Health, Denver, Colorado; Department of Immunology, University of Colorado School of Medicine, Aurora, Colorado; Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado; Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado. Electronic address: [email protected].
² Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
³ Program in Cell Biology, Department of Pediatrics, National Jewish Health, Denver, Colorado; Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.

Abstract

This commentary highlights the article by Sisson et al, which establishes the importance of the myocardin-related transcription factor/serum response factor signaling pathway as a therapeutic target in the management of fibrotic lung disease.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Animals
Apoptosis*
Humans
Lung / metabolism*
Lung / pathology*
Mesoderm / pathology*
Serum Response Factor / metabolism*
Signal Transduction*
Trans-Activators / metabolism*

Substances

Serum Response Factor
Trans-Activators

Abstract

Publication types

MeSH terms

Substances

Grants and funding